OCTOBER - 202019Bioneer's popular MDx system ExiStationTM was developed during the swine-flu pandemic in 2008 to offer an efficient, automated, and pipetting-free system that minimizes hands-on steps from nucleic acid extraction to PCR processes. ExiStationTM is equipped with an aerosol protection system to prevent contamination and secondary infection by users and provides an accurate test result. Similarly, its AccuPower® ZIKV (DENV, CHIKV) Multiplex Real-Time RT-PCR Kit was the first multiplex in-vitro diagnostic test sanctioned by the World Health Organization (WHO) during the ZIKA virus epidemic in 2016. These kits can detect RNA targets from clinical samples with high sensitivity and specificity by eliminating non-specific synthesis and amplification. In addition to these diseases, Bioneer also contributes to public health by supplying more than 40 kinds of kits for diagnostics of HIV, Hepatitis B, Hepatitis C, sexually-transmitted infections, and Tuberculosis. It is also the first and the only company in Asia to receive CE-IVD, List A certification for HIV-1, HBV, and HCV viral load assays.Such comprehensive and proven capabilities are now at the core of Bioneer's phenomenal work during the ongoing COVID-19 pandemic. Bioneer has already extended its expertise to more than 70 countries around the world with its MDx system ExiStationTM, and the COVID-19 detection kits:AccuPower® SARS-CoV-2 Multiplex RT-PCR Kit and AccuPower® COVID-19 RT-PCR Kit. The AccuPower® SARS-CoV-2 Multiplex RT-PCR Kit, in particular, helps in the detection of specific genes specific to the COVID-19--E, N, and RdRP genes.Augmenting these efforts, Bioneer has recently initiated two subsidiaries: AceBiome Inc. and siRNAgen Therapeutics Corp. While AceBiome Inc. specializes in probiotics supplement development for disease prevention, siRNAgen Therapeutics Corp. specializes in developing RNA interference therapeutics for anti-fibrotic, anti-proliferative, anti-cancer, and COVID-19. And through these two subsidiaries, Bioneer plans to develop an innovative diagnostic and therapeutic platform based on genomic technologies to make a healthier future for humanity.Moving ahead with such pivotal grace, Bioneer is now ramping up its production capacity to meet the increasing customer demands. Besides two production and research facilities in Korea, Bioneer has a distribution facility in the U.S. The company is also pursuing complete automation of hands-on processing. Through these initiatives,Bioneer is currently poised to develop next-generation technologies in the post-genome era through the invention of new biochemistry and instruments. Bioneer is also about to launch a near-patient point-of-care molecular diagnostic platform called IRON-qPCRTM, which can test the most infected pathogens and antimicrobial resistance within 30 minutes. "We believe that IRON-qPCRTM will be an essential tool for blocking infectious diseases, such as COVID-19, RSV, Influenza A and B, and TB. It will be a landmark in the progress of precision medicine," concludes Dr.Park. Bioneer has created a full line and differentiated MDx systems composed of 96-well/384-well real-time PCR instruments and 16/48/96 automatic extractors with a high throughput of up to 5,000 tests per dayDr. Han-Oh Park
< Page 9 | Page 11 >